Focused Ultrasound Proposed as Noninvasive Modulator of PGC-1α Pathways for Neuroprotection in Neurological Diseases

The brain's high energy demand makes mitochondrial performance critical for synaptic resilience and neuronal survival. Peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) is a master transcriptional regulator of mitochondrial biogenesis, antioxidant defenses, and neuroplasticity. Its dysregulation is a convergent pathogenic mechanism across Parkinson's disease, Alzheimer's disease, Huntington's disease, stroke, and neuropsychiatric disorders. Conventional pharmacological PGC-1α activators face significant translational barriers, including poor blood-brain barrier penetration and off-target effects, necessitating novel delivery or activation strategies.

This comprehensive review synthesizes existing mechanistic evidence to propose focused ultrasound as a noninvasive platform for modulating PGC-1α pathways in neurological disease. The authors systematically integrated findings on ultrasound's ability to induce membrane tension, activate mechanosensitive channels like Piezo1 and TRAAK, and trigger downstream kinase signaling. They also explored indirect priming mechanisms, including reversible blood-brain barrier opening, hemodynamic augmentation, and glial immunomodulation, to construct a hypothesis-generating roadmap for future research.

The review posits that focused ultrasound can directly modulate PGC-1α activity through mechanotransduction. It highlights evidence that ultrasound induces membrane tension, which in turn activates mechanosensitive channels such as Piezo1 and TRAAK. This activation is hypothesized to trigger downstream kinase signaling pathways that ultimately influence PGC-1α expression and activity. Indirectly, focused ultrasound may also facilitate PGC-1α-dependent neuroprotection by reversibly opening the blood-brain barrier, enhancing cerebral hemodynamics, and modulating glial immune responses. The authors integrate concepts like mitochondrial synapses, PGC-1α isoform diversity, and theranostic architectures, defining mechanistic opportunities and disease-specific strategies for ultrasonic modulation. They emphasize the potential for regionally precise modulation, which could be critical for targeted therapies.

The full ultrasound → PPARGC1A → neuroprotection chain in brain tissue remains a working hypothesis rather than a demonstrated therapeutic mechanism.